Nitric oxide, oxidative excess, and vascular complications of diabetes mellitus

Current Hypertension Reports

Volumn 6, Issue 2, 2004, Pages 85-89

  Endemann, Dierk H ^a   Schiffrin, Ernesto L ^a  

^a CLIN RESEARCH INSTITUTE OF MONTREAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALT 117; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLUCOSE; INSULIN; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PROTEIN KINASE C; PROTEIN KINASE C INHIBITOR; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; UNCLASSIFIED DRUG; XANTHINE OXIDASE;

ADULT; ANTIOXIDANT ACTIVITY; ARTICLE; ATHEROSCLEROTIC PLAQUE; BIOAVAILABILITY; CARDIOVASCULAR DISEASE; DIABETES MELLITUS; DRUG MECHANISM; ENDOTHELIUM LESION; ENZYME ACTIVATION; EPIDEMIC; GLUCOSE BLOOD LEVEL; HUMAN; HYPERTENSION; INFLAMMATION; MITOCHONDRION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PREVALENCE; RISK ASSESSMENT; RISK REDUCTION; SIGNAL TRANSDUCTION; VASCULAR DISEASE; ANIMAL; DIABETIC ANGIOPATHY; PHYSIOLOGY; REVIEW; VASCULAR ENDOTHELIUM;

ANIMALS; DIABETES COMPLICATIONS; DIABETES MELLITUS; DIABETIC ANGIOPATHIES; ENDOTHELIUM, VASCULAR; HUMANS; NITRIC OXIDE; OXIDATIVE STRESS; VASCULAR DISEASES;

EID: 4644262824     PISSN: 15226417     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11906-004-0081-x     Document Type: Article

References (53)

1. Narayan KM, Boyle JP, Thompson TJ, et al.: Lifetime risk for diabetes mellitus in the United States. JAMA 2003, 290:1884-1890.
2. Rizzoni D, Porteri E, Guelfi D, et al.: Structural alterations in subcutaneous small arteries of normotensive and hypertensive patients with non-insulin-dependent diabetes mellitus. Circulation 2001, 103:1238-1244.
3. Schofield I, Malik R, Izzard A, et al.: Vascular structural and functional changes in type 2 diabetes mellitus: evidence for the roles of abnormal myogenic responsiveness and dyslipidemia. Circulation 2002, 106:3037-3043.
4. Wen Y, Skidmore JC, Porter-Turner MM, et al.: Relationship of glycation, antioxidant status and oxidative stress to vascular endothelial damage in diabetes. Diabetes Obes Metab 2002, 4:305-308.
5. Schram MT, Chaturvedi N, Schalkwijk C, et al.: Vascular risk factors and markers of endothelial function as determinants of inflammatory markers in type 1 diabetes: the EURODIAB Prospective Complications Study. Diabetes Care 2003, 26:2165-2173.
6. Heitzer T, Schlinzig T, Krohn K, et al.: Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease. Circulation 2001, 104: 673-2678.
7. Stehouwer CD, Gall MA, Twisk JW, et al.: Increased urinary albumin excretion, endothelial dysfunction, and chronic low-grade inflammation in type 2 diabetes: progressive, interrelated, and independently associated with risk of death. Diabetes 2002, 51:1157-1165.
8. Frisbee JC, Stepp DW: Impaired NO-dependent dilation of skeletal muscle arterioles in hypertensive diabetic obese Zucker rats. Am J Physiol Heart Circ Physiol 2001, 281:H1304-H1311.
9. Kim YK, Lee MS, Son SM, et al.: Vascular NADH oxidase is involved in impaired endothelium-dependent vasodilation in OLETF rats, a model of type 2 diabetes. Diabetes 2002, 51: 22-527.
10. Popov D, Costache G, Georgescu A, Enache M: Beneficial effects of L-arginine supplementation in experimental hyperlipemia-hyperglycemia in the hamster. Cell Tissue Res 2002, 308:109-120.
11. Yu PK, Yu DY, Cringle SJ, Su EN: Tetrahydrobiopterin reverses the impairment of acetylcholine-induced vasodilatation in diabetic ocular microvasculature. J Ocul Pharmacol Ther 2001, 17:123-129.
12. Ouvina SM, La Greca RD, Zanaro NL, et al.: Endothelial dysfunction, nitric oxide and platelet activation in hypertensive and diabetic type II patients. Thromb Res 2001, 102:107-114.
13. Tretjakovs P, Kalnins U, Dabina I, et al.: Nitric oxide production and arachidonic acid metabolism in platelet membranes of coronary heart disease patients with and without diabetes. Med Princ Pract 2003, 12:10-16.
14. Creager MA, Luscher TF, Cosentino F, Beckman JA: Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: Part I. Circulation 2003, 108:1527-1532.
15. Sonoki K, Iwase M, Iino K, et al.: Atherogenic role of lysophosphatidylcholine in low-density lipoprotein modified by phospholipase A2 and in diabetic patients: protection by nitric oxide donor. Metabolism 2003, 52:308-314.
16. Ramana KV, Chandra D, Srivastava S, et al.: Nitric oxide regulates the polyol pathway of glucose metabolism in vascular smooth muscle cells. FASEB J 2003, 17:417-425.
17. Hamuro M, Polan J, Natarajan M, Mohan S: High glucose induced nuclear factor kappa B mediated inhibition of endothelial cell migration. Atherosclerosis 2002, 162:277-287.
18. Napoli C, Lerman LO, de Nigris F, et al.: Glycoxidized low-density lipoprotein downregulates endothelial nitric oxide synthase in human coronary cells. J Am Coll Cardiol 2002, 40:1515-1522.
19. Cosentino F, Hishikawa K, Katusic ZS, Luscher TF: High glucose increases nitric oxide synthase expression and superoxide anion generation in human aortic endothelial cells. Circulation 1997, 96:25-28.
20. Chen J, Brodsky SV, Goligorsky DM, et al.: Glycated collagen I induces premature senescence-like phenotypic changes in endothelial cells. Circ Res 2002, 90:1290-1298.
21. Ceriello A, Mercuri F, Quagliaro L, et al.: Detection of nitrotyrosine in the diabetic plasma: evidence of oxidative stress. Diabetologia 2001, 44:834-838.
22. Laursen JB, Somers M, Kurz S, et al.: Endothelial regulation of vasomotion in apoE-deficient mice: implications for interactions between peroxynitrite and tetrahydrobiopterin. Circulation 2001, 103:1282-1288.
23. Griendling KK, FitzGerald GA: Oxidative stress and cardiovascular injury: Part I: basic mechanisms and in vivo monitoring of ROS. Circulation 2003, 108:1912-1916.
24. Szabo C, Mabley JG, Moeller SM, et al.: Part I: Pathogenetic role of peroxynitrite in the development of diabetes and diabetic vascular complications: studies with FP15, a novel potent peroxynitrite decomposition catalyst. Mol Med 2002, 8: 71-580.
25. Stalker TJ, Skvarka CB, Scalia R: A novel role for calpains in the endothelial dysfunction of hyperglycemia. FASEB J 2003, 17:1511-1513.
26. Venugopal SK, Devaraj S, Yuhanna I, et al.: Demonstration that C-reactive protein decreases eNOS expression and bioactivity in human aortic endothelial cells. Circulation 2002, 106:1439-1441.
27. Bucala R, Tracey KJ, Cerami A: Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilatation in experimental diabetes. J Clin Invest 1991, 87:432-438.
28. Montagnani M, Ravichandran LV, Chen H, et al.: Insulin receptor substrate-1 and phosphoinositide-dependent kinase-1 are required for insulin-stimulated production of nitric oxide in endothelial cells. Mol Endocrinol 2002, 16:1931-1942.
29. Osman AA, Pendergrass M, Koval J, et al.: Regulation of MAP kinase pathway activity in vivo in human skeletal muscle. Am J Physiol Endocrinol Metab 2000, 278:E992-E999.
30. Cusi K, Maezono K, Osman A, et al.: Insulin resistance differentially affects the PI 3-kinase- and MAP kinase-mediated signaling in human muscle. J Clin Invest 2000, 105:311-320.
31. Federici M, Menghini R, Mauriello A, et al.: Insulin-dependent activation of endothelial nitric oxide synthase is impaired by O-linked glycosylation modification of signaling proteins in human coronary endothelial cells. Circulation 2002, 106: 66-472.
32. Sartipy P, Loskutoff DJ: Monocyte chemoattractant protein 1 in obesity and insulin resistance. Proc Natl Acad Sci U S A 2003, 100:7265-7270.
33. Matsubara M, Hayashi N, Jing T, Titani K: Regulation of endothelial nitric oxide synthase by protein kinase C. J Biochem (Tokyo) 2003, 133:773-781.
34. Inoguchi T, Sonta T, Tsubouchi H, et al.: Protein kinase C-dependent increase in reactive oxygen species (ROS) production in vascular tissues of diabetes: role of vascular NAD(P)H oxidase. J Am Soc Nephrol 2003, 14:S227-S232.
35. Nangle MR, Cotter MA, Cameron NE: Protein kinase C beta inhibition and aorta and corpus cavernosum function in streptozotocin-diabetic mice. Eur J Pharmacol 2003, 475: 9-106.
36. Tuttle KR, Anderson PW: A novel potential therapy for diabetic nephropathy and vascular complications: protein kinase C beta inhibition. Am J Kidney Dis 2003, 42:456-465.
37. Nishikawa T, Edelstein D, Du XL, et al.: Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 2000, 404:787-790.
38. Du XL, Edelstein D, Dimmeler S, et al.: Hyperglycemia inhibits endothelial nitric oxide synthase activity by posttranslational modification at the Akt site. J Clin Invest 2001, 108:1341-1348.
39. Uemura S, Matsushita H, Li W, et al.: Diabetes mellitus enhances vascular matrix metalloproteinase activity: role of oxidative stress. Circ Res 2001, 88:1291-1298.
40. Chen X, Touyz RM, Park JB, Schiffrin EL: Antioxidant effects of vitamins C and E are associated with altered activation of vascular NADPH oxidase and superoxide dismutase in stroke-prone SHR. Hypertension 2001, 38:606-611.
41. Zhang L, Zalewski A, Liu Y, et al.: Diabetes-induced oxidative stress and low-grade inflammation in porcine coronary arteries. Circulation 2003, 108:472-478.
42. Vlassara H: The AGE-receptor in the pathogenesis of diabetic complications. Diabetes Metab Res Rev 2001, 17: 36-443.
43. Kass DA, Shapiro EP, Kawaguchi M, et al.: Improved arterial compliance by a novel advanced glycation end-product crosslink breaker. Circulation 2001, 104:1464-1470.
44. Makita Z, Radoff S, Rayfield EJ, et al.: Advanced glycosylation end products in patients with diabetic nephropathy. N Engl J Med 1991, 325:836-842.
45. Bucciarelli LG, Wendt T, Qu W, et al.: RAGE blockade stabilizes established atherosclerosis in diabetic apolipoprotein E-null mice. Circulation 2002, 106:2827-2835.
46. Ogihara T, Asano T, Ando K, et al.: Angiotensin II-induced insulin resistance is associated with enhanced insulin signaling. Hypertension 2002, 40:872-879.
47. Kitada M, Koya D, Sugimoto T, et al.: Translocation of glomerular p47phox and p67phox by protein kinase C-beta activation is required for oxidative stress in diabetic nephropathy. Diabetes 2003, 52:2603-2614.
48. Desco MC, Asensi M, Marquez R, et al.: Xanthine oxidase is involved in free radical production in type 1 diabetes: protection by allopurinol. Diabetes 2002, 51:1118-1124.
49. Matsumoto S, Koshiishi I, Inoguchi T, et al.: Confirmation of superoxide generation via xanthine oxidase in streptozotocin-induced diabetic mice. Free Radic Res 2003, 37:767-772.
50. Petersen KF, Befroy D, Dufour S, et al.: Mitochondrial dysfunction in the elderly: possible role in insulin resistance. Science 2003, 300:1140-1142.
51. Du X, Matsumura T, Edelstein D, et al.: Inhibition of GAPDH activity by poly(ADP-ribose) polymerase activates three major pathways of hyperglycemic damage in endothelial cells. J Clin Invest 2003, 112:1049-1057.
52. Endemann D, Pu Q, De Ciuceis C, et al.: Resistance arteries in type 2 diabetic patients under antihypertensive treatment show marked remodeling. Hypertension 2004, In press.
53. Schiffrin EL, Amiri F, Benkirane K, et al.: Peroxisome proliferator-activated receptors: vascular and cardiac effects in hypertension. Hypertension 2003, 42:664-668.